Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer^®, a biodegradable, bio-inert material that enhances the pharmacokinetics and safety of drugs.  Mersana’s pipeline includes compounds with activity against multiple tumor types and human proof-of-concept.  Mersana’s lead product candidate, XMT-1001, entered the clinic in 2007.

	About Our Name Mersana Therapeutics is named after the Russian goddess of the harvest. Mersana’s strategy is to identify promising cancer agents that faltered in development despite evidence of clinical efficacy and to bring them to fruition.